Business Context and Reporting Period
This Form 8-K is a current report filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on June 21, 2006. The filing discloses the entry into a material definitive agreement regarding the amendment of director compensation schedules, effective retroactively as of May 15, 2006.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on governance and compensation structures.
Material Changes
The Board of Directors amended the compensation payable to non-employee directors. The new structure includes:
- Board Membership: $2,500 per quarter per director; $3,750 per quarter for the Chairperson.
- Audit Committee: $2,500 per quarter for members; $5,000 per quarter for the Chairperson.
- Compensation Committee: $1,250 per quarter for members; $2,500 per quarter for the Chairperson.
- Nominating and Governance Committee: $1,250 per quarter for members; $2,500 per quarter for the Chairperson.
- Meeting Fees: Effective May 15, 2006, directors receive $1,000 for in-person attendance or $500 for telephone attendance at meetings exceeding 15 minutes, excluding the first four Board meetings, first four Audit Committee meetings, first two Compensation Committee meetings, and first Nominating Committee meeting of each calendar year.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the compensation agreement itself.
Investor Verification Checklist
- Verify the total annual cost of the new director compensation package based on the number of directors and expected meeting frequency.
- Confirm the retroactive effective date of May 15, 2006, and its impact on the current quarter's expenses.
- Review the company's cash position to ensure liquidity is sufficient to cover the increased director fees.
- Note the discrepancy between the requested company name (Savara Inc.) and the actual registrant (AdventRX Pharmaceuticals, Inc.).